All about PSY DREAM. Psychiatric drug registration, evaluation & all-inclusive monitoring

Epidemiologia e Psichiatria Sociale

Volumn 14, Issue 1, 2005, Pages 15-21

  Lehmann, Peter ^a  

^a NONE   (Germany)

Author keywords

Evaluation; Involvement of users; Monitoring; Psychiatric drugs; Registration

Indexed keywords

ALLENOPAR; AROXAT; AROXETIN; CASBOL; CHLORPROMAZINE; CLOZAPINE; DAPAROX; ENNOS; EUPLIX; FROSINOR; HALOPERIDOL; NEUROLEPTIC AGENT; OXET; PAROLICH; PAROXAT; PAROXEDURA; PAROXETIN; PAROXETINE; PAXTINE; QUETIAPINE; SEREUPIN; SERTINDOLE;

BREAST CANCER; CANCER RISK; CONFERENCE PAPER; COST; DECISION MAKING; DELUSION; DISEASE SEVERITY; DRUG DEPENDENCE; DRUG MONITORING; DRUG SCREENING; DRUG USE; DYSKINESIA; EXTRAPYRAMIDAL SYMPTOM; HALLUCINATION; HUMAN; HUMAN RIGHTS; MEDICAL ETHICS; MEDICAL SOCIETY; NONHUMAN; PRACTICE GUIDELINE; PROFESSIONAL STANDARD; PSYCHOSIS; SIDE EFFECT; SUICIDE; TARDIVE DYSKINESIA; VIOLENCE; WITHDRAWAL SYNDROME;

EID: 15244361945     PISSN: 1121189X     EISSN: None     Source Type: Journal    
DOI: 10.1017/s1121189x00001883     Document Type: Conference Paper

References (33)

1. Ayd F.J. (1975), The depot fluphenazines. American Journal of Psychiatry 132, 491-500.
2. Benkert O. & Hippius H. (1980). Psychiatrische Pharmakotherapie, 3. ed. Springer: Berlin/Heidelberg/New York.
3. Bradstreet S. & Norris R. (Ed.) (2004). All you need to know? Scottish Survey of People's Experience of Psychiatric Drugs. Scottish Association for Mental Health: Glasgow 2004. Retrieved November 19, 2004, from http://www.samh.org.uk/drugs%20report/Full%20report1.htm
4. Cobb A., Darton K. & Juttla K. (2001). Mind's Yellow Card for Reporting Drug Side Effects. A Report of Users' Experiences. Mind Publications: London.
5. Degkwitz R. & Luxenburger O. (1965). Das terminale extrapyramidale Insuffizienz- bzw. Defektsyndrom infolge chronischer Anwendung von Neurolepticis. Nervenarzt 36, 173-175.
6. Ebner G. (2003). Aktuelles aus der Psychopharmakologie. Das Wichtigste vom ECNP-Kongress. Psychiatrie (Switzerland), online edition, No. 1, 29-32. Retrieved July 13 2004, from http:// www.medpoint.ch/frame.asp?ru= dokument&ArtikelID=10116
7. ENMESH, European Network for Mental Health Service Evaluation (2004). Conference Programme. ENMESH: London.
8. ENUSP, European Network of (ex-) Users and Survivors of Psychiatry (1999). Final statement. In The Luxembourg-Report. Documents from the congress "Into the Next Millennium: Moving Forward to Our Own Future," Luxembourg, February 19-21, 1999. Retrieved September 2, 2004, from http://www.enusp.org/congresses/luxembourg/final.htm
9. ENUSP, European Network of (ex-)Users and Survivors of Psychiatry (2003a). The European Newsletter of (ex-) Users and Survivors of Psychiatry 11 (special issue). Retrieved September 2, 2004, from http://www.enusp.org/ newsletter/2003-6.pdf
10. ENUSP, European Network of (ex-)Users and Survivors of Psychiatry (2003b). The European Newsletter of (ex-) Users and Survivors of Psychiatry 12 (special issue). Retrieved September 2, 2004, from http://www.enusp.org/ newsletter/2003-12.pdf
11. Frank L.R. (1978). The History of Shock Treatment. Self Publication: San Francisco.
12. Grimond M. (2004). Drug firms settles Seroxat research claim. The Independent, August 27. Retrieved August 28, 2004, from http://news.independent. co.uk/business/news/story.jsp?story=5555 32
13. Halbreich U., Shen J. & Panaro V. (1996). Are chronic psychiatric patients at increased risk for developing breast cancer? American Journal of Psychiatry 153, 559-560.
14. Helmchen H. (1981). Aufklärung und Einwilligung bei psychisch Kranken. In Psychiatrie und Rechtsstaat (ed. M. Bergener and F. Andritsch), pp. 79-96. Luchterhand: Darmstadt.
15. Kempker K. & Lehmann P. (ed.) (1993). Statt Psychiatrie. Antipsychiatrieverlag: Berlin.
16. Lehmann P. (1981). Was Sie schon immer über Psychopharmaka wissen wollten. Die Irren-Offensive-Zeitschrift von Ver-rücklen gegen Psychiatrie 1, 16-21.
17. Lehmann P. (1986). Der chemische Knebel-Warum Psychiater Neuroleptika verabreichen. Antipsychiatrieverlag: Berlin.
18. Lehmann P. (1996a). Schöne neue Psychiatrie. Vol. 1: Wie Chemie und Strom auf Geist und Psyche wirken. Antipsychiatrieverlag: Berlin.
19. Lehmann P. (1996b). Schöne neue Psychiatrie. Vol. 2: Wie Psychopharmaka den Körper verändern. Antipsychiatrieverlag: Berlin.
20. Lehmann P. (Ed.) (1998). Psychopharmaka absetzen. Erfolgreiches Absetzen von Neuroleptika, Antidepressiva, Lithium, Carbamazepin und Tranquilizern. Antipsychiatrieverlag: Berlin.
21. Lehmann P. (1999). Forum. The Declaration of Madrid and current psychiatric practice: users' and advocates' views. Current Opinion in Psychiatry 12, 6-7. Retrieved September 2, 2004, from http://www.enusp.org/documents/ curr_opinion.htm
22. Lehmann P. (Ed.) (2004). Coming off Psychiatric Drugs. Successful Withdrawal from Neuroleptics, Antidepressants, Lithium, Carbamazepine and Tranquilizers. Peter Lehmann Publishing: Berlin/Eugene/Shrewsbury.
23. Müller P. (1981). Depressive Syndrome im Verlauf schizophrener Psychosen. Enke: Stuttgart.
24. Oaks, D. (1982/83). Thorazine, Mellaril, Haldol, Prolixin: bizarre facts about neuroleptics. Madness Network News 6, 11-13.
25. Pedler M. (1999). Forum. The Declaration of Madrid and current psychiatric practice: users' and advocates' views. Current Opinion in Psychiatry 12, 3.
26. Peeck G., von Seckendorff C. & Heinecke P. (1995). Ergebnis der Umfrage unter den Mitgliedern des Bundesverbandes Psychiatrieerfahrener zur Qualität der psychiatrischen Versorgung. Sozialpsychiatrische Informationen 25(4), 30-34. Retrieved September 2, 2004, from http://www.bpe-online.de/ infopool /recht/pb/umfrage.htm
27. Reimer F. (1965). Das "Absetzungs"-Delir. Nervenarzt 34, 446-447.
28. Sommer H. & Quandt J. (1970). Langzeitbehandlung mit Crhlorpromazin im Tierexperiment. Fortschritte der Neurologie-Psychiatrie und ihrer Grenzgebiete 38, 466-491.
29. Tornatore F.L., Sramek J.J., Okeya B.L. & Pi E.H. (1987). Reactions to Psychotropic Medication. Plenum Pub Corp.: New York/London.
30. Tornatore F.L., Sramek J.J., Okeya B.L. & Pi E.H. (1991). Unerwünschte Wirkungen von Psychopharmaka. Thieme: Stuttgart/New York.
31. Ungerstedt U. & Ljungberg T. (1977). Behavioral patterns related to dopamine neurotransmission. Advances in Biochemical Psychopharmacology 16, 193-199.
32. World Health Organization (1997). Quality Assurance in Mental Health Care. Human Rights of People with Mental Disorders, Unpublished draft. WHO: Geneva.
33. World Health Organization (1999). Conclusions of "Balancing Mental Health Promotion and Mental Health Care: A Joint World Health Organization / European Commission Meeting," Brussels, 22-24 April 1999. In World Health Organization & European Commission: Balancing Mental Health Promotion and Mental Health Care: A Joint World Health Organization/European Commission Meeting. Brochure MNH/NAM/99.2. Brussels: WHO 1999, 9-10. Retrieved September 2, 2004, from http://www.enusp. org/documents/consensus.htm